ArticleScientific reports2026
VCAN promotes the progression and recurrence of esophageal squamous cell carcinoma by remodeling the tumor microenvironment.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Versican (VCAN), an extracellular matrix (ECM) proteoglycan, is implicated in tumor-related immunity and inflammation, but its specific function and mechanism in esophageal squamous cell carcinoma (ESCC) remain unclear. Public databases, including Gene Expression Profiling Interactive Analysis (GEPIA) and Tumor Immune Estimation Resource (TIMER), were used to analyze VCAN expression and its correlation with prognosis. Functional assays, including Cell Counting Kit-8 (CCK-8), 5-ethynyl-2’-deoxyuridine (EdU), wound healing, Transwell invasion, and tube formation assays, were conducted to evaluate the effects of VCAN on ESCC cell proliferation, migration, invasion, and angiogenesis in vitro. Nude mouse xenograft, lung metastasis, and tumor recurrence models were established to assess tumor growth, pulmonary metastasis, and cisplatin (CDDP) resistance in vivo. Immune cell profiles were analyzed using flow cytometry, immunohistochemistry (IHC), and enzyme-linked immunosorbent assay (ELISA). VCAN was significantly upregulated in ESCC and was associated with poor survival. VCAN promoted ESCC cell proliferation, migration, invasion, angiogenesis, tumor growth, and pulmonary metastasis. Mechanistically, VCAN remodeled the immunosuppressive tumor microenvironment (TME) by inducing M2 macrophage polarization and impairing the activation and cytotoxicity of CD4⁺ and CD8⁺ T cells. In CDDP-treated mice, VCAN knockdown delayed tumor recurrence and alleviated the immunosuppressive TME, whereas VCAN overexpression accelerated recurrence. VCAN upregulation promoted ESCC progression and recurrence by modulating M2 macrophages and suppressing T cells. Targeting VCAN may represent a potential immunotherapy strategy for ESCC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.